| Literature DB >> 32519232 |
Volkan Ince1, Sami Akbulut2, Emrah Otan2, Veysel Ersan2, Serdar Karakas2, Tolga Tevfik Sahin2, Brian I Carr2, Adil Baskiran2, Emine Samdanci3, Harika Gozukara Bag4, Cemalettin Koc2, Sertac Usta2, Fatih Ozdemir2, Bora Barut2, Fatih Gonultas2, Baris Sarici2, Koray Kutluturk2, Murat Sait Dogan2, Dincer Ozgor2, Mustafa Dikilitas5, Murat Harputluoglu6, Murat Aladag6, Ramazan Kutlu7, Ilknur Varol8, Abuzer Dirican2, Cemalettin Aydin2, Burak Isik2, Cengiz Ara2, Cuneyt Kayaalp2, Sukru Emre2, Sezai Yilmaz2.
Abstract
Survival was examined from a Turkish liver transplant center of patients with HCC, to identify prognostic factors. Data from 215 patients who underwent predominantly live donor liver transplant for HCC at our institute over 12 years were included in the study and prospectively recorded. They were 152 patients within and 63 patients beyond Milan criteria. Patients beyond Milan criteria were divided into two groups according to presence or absence of tumor recurrence. Recurrence-associated factors were analyzed. These factors were then applied to the total cohort for survival analysis. We identified four factors, using multivariate analysis, that were significantly associated with tumor recurrence. These were maximum tumor diameter, degree of tumor differentiation, and serum AFP and GGT levels. A model that included all four of these factors was constructed, the 'Malatya criteria.' Using these Malatya criteria, we estimated DFS and cumulative survival, for patients within and beyond these criteria, and found statistically significant differences with improved survival in patients within Malatya criteria of 1, 5, and 10-year overall survival rates of 90.1%, 79.7%, and 72.8% respectively, which compared favorably with other extra-Milan extended criteria. Survival of our patients within the newly defined Malatya criteria compared favorably with other extra-Milan extended criteria and highlight the usefulness of serum AFP and GGT levels in decision-making.Entities:
Keywords: Hepatic; Live donor; Malatya criteria; Malignancy
Year: 2020 PMID: 32519232 DOI: 10.1007/s12029-020-00424-w
Source DB: PubMed Journal: J Gastrointest Cancer